These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 21847689)

  • 1. Quantitative PK-PD model-based translational pharmacology of a novel kappa opioid receptor antagonist between rats and humans.
    Chang C; Byon W; Lu Y; Jacobsen LK; Badura LL; Sawant-Basak A; Miller E; Liu J; Grimwood S; Wang EQ; Maurer TS
    AAPS J; 2011 Dec; 13(4):565-75. PubMed ID: 21847689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological characterization of 2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for κ-opioid receptors.
    Grimwood S; Lu Y; Schmidt AW; Vanase-Frawley MA; Sawant-Basak A; Miller E; McLean S; Freeman J; Wong S; McLaughlin JP; Verhoest PR
    J Pharmacol Exp Ther; 2011 Nov; 339(2):555-66. PubMed ID: 21821697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the agonist PET radioligand [¹¹C]GR103545 to image kappa opioid receptor in humans: kinetic model selection, test-retest reproducibility and receptor occupancy by the antagonist PF-04455242.
    Naganawa M; Jacobsen LK; Zheng MQ; Lin SF; Banerjee A; Byon W; Weinzimmer D; Tomasi G; Nabulsi N; Grimwood S; Badura LL; Carson RE; McCarthy TJ; Huang Y
    Neuroimage; 2014 Oct; 99():69-79. PubMed ID: 24844744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and discovery of a selective small molecule κ opioid antagonist (2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine, PF-4455242).
    Verhoest PR; Basak AS; Parikh V; Hayward M; Kauffman GW; Paradis V; McHardy SF; McLean S; Grimwood S; Schmidt AW; Vanase-Frawley M; Freeman J; Van Deusen J; Cox L; Wong D; Liras S
    J Med Chem; 2011 Aug; 54(16):5868-77. PubMed ID: 21744827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of novel kappa opioid receptor antagonists on dopamine neurons using acute brain slice electrophysiology.
    Margolis EB; Wallace TL; Van Orden LJ; Martin WJ
    PLoS One; 2020; 15(12):e0232864. PubMed ID: 33373369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic Relationships between Duration of Action of JDTic-like Kappa-Opioid Receptor Antagonists and Their Brain and Plasma Pharmacokinetics in Rats.
    Owens SM; Pollard GT; Howard JL; Fennell TR; Snyder RW; Carroll FI
    ACS Chem Neurosci; 2016 Dec; 7(12):1737-1745. PubMed ID: 27700049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral administration of κ-opioid receptor antagonist stimulates gonadotropin-releasing hormone pulse generator activity in ovariectomized, estrogen-treated female goats.
    Sasaki T; Ito D; Sonoda T; Morita Y; Wakabayashi Y; Yamamura T; Okamura H; Oishi S; Noguchi T; Fujii N; Uenoyama Y; Tsukamura H; Maeda KI; Matsuda F; Ohkura S
    Domest Anim Endocrinol; 2019 Jul; 68():83-91. PubMed ID: 30908995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kappa opioid receptor antagonists: A possible new class of therapeutics for migraine prevention.
    Xie JY; De Felice M; Kopruszinski CM; Eyde N; LaVigne J; Remeniuk B; Hernandez P; Yue X; Goshima N; Ossipov M; King T; Streicher JM; Navratilova E; Dodick D; Rosen H; Roberts E; Porreca F
    Cephalalgia; 2017 Jul; 37(8):780-794. PubMed ID: 28376659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Species differences in the effects of the κ-opioid receptor antagonist zyklophin.
    Sirohi S; Aldrich JV; Walker BM
    Alcohol; 2016 Mar; 51():43-9. PubMed ID: 26992699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140).
    Guerrero M; Urbano M; Kim EK; Gamo AM; Riley S; Abgaryan L; Leaf N; Van Orden LJ; Brown SJ; Xie JY; Porreca F; Cameron MD; Rosen H; Roberts E
    J Med Chem; 2019 Feb; 62(4):1761-1780. PubMed ID: 30707578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physical presence of nor-binaltorphimine in mouse brain over 21 days after a single administration corresponds to its long-lasting antagonistic effect on κ-opioid receptors.
    Patkar KA; Wu J; Ganno ML; Singh HD; Ross NC; Rasakham K; Toll L; McLaughlin JP
    J Pharmacol Exp Ther; 2013 Sep; 346(3):545-54. PubMed ID: 23853171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translational and pharmacokinetic-pharmacodynamic application for the clinical development of GDC-0334, a novel TRPA1 inhibitor.
    Chan P; Ding HT; Liederer BM; Mao J; Belloni P; Chen L; Gao SS; Joseph V; Yang X; Lin JS; Mitra MS; Putnam WS; Quartino A; Bauer RN; Pan L
    Clin Transl Sci; 2021 Sep; 14(5):1945-1954. PubMed ID: 34058071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Further characterization of the discriminative stimulus effects of spiradoline.
    Holtzman SG
    Pharmacol Biochem Behav; 2000 Jul; 66(3):517-22. PubMed ID: 10899364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects.
    Lowe SL; Wong CJ; Witcher J; Gonzales CR; Dickinson GL; Bell RL; Rorick-Kehn L; Weller M; Stoltz RR; Royalty J; Tauscher-Wisniewski S
    J Clin Pharmacol; 2014 Sep; 54(9):968-78. PubMed ID: 24619932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a robust, sensitive and selective liquid chromatography-tandem mass spectrometry assay for the quantification of the novel macrocyclic peptide kappa opioid receptor antagonist [D-Trp]CJ-15,208 in plasma and application to an initial pharmacokinetic study.
    Khaliq T; Williams TD; Senadheera SN; Aldrich JV
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Aug; 1028():11-15. PubMed ID: 27318293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders.
    Rorick-Kehn LM; Witkin JM; Statnick MA; Eberle EL; McKinzie JH; Kahl SD; Forster BM; Wong CJ; Li X; Crile RS; Shaw DB; Sahr AE; Adams BL; Quimby SJ; Diaz N; Jimenez A; Pedregal C; Mitch CH; Knopp KL; Anderson WH; Cramer JW; McKinzie DL
    Neuropharmacology; 2014 Feb; 77():131-44. PubMed ID: 24071566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent and Selective Tetrahydroisoquinoline Kappa Opioid Receptor Antagonists of Lead Compound (3 R)- N-[1 R)-1-(Cyclohexylmethyl)-2-methylpropyl]-7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (CDTic).
    Kormos CM; Ondachi PW; Runyon SP; Thomas JB; Mascarella SW; Decker AM; Navarro HA; Fennell TR; Snyder RW; Carroll FI
    J Med Chem; 2018 Sep; 61(17):7546-7559. PubMed ID: 30032602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Behavioral Pharmacology of Novel Kappa Opioid Receptor Antagonists in Rats.
    Page S; Mavrikaki MM; Lintz T; Puttick D; Roberts E; Rosen H; Carroll FI; Carlezon WA; Chartoff EH
    Int J Neuropsychopharmacol; 2019 Nov; 22(11):735-745. PubMed ID: 31613314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of serotonin transporter function by kappa-opioid receptor ligands.
    Sundaramurthy S; Annamalai B; Samuvel DJ; Shippenberg TS; Jayanthi LD; Ramamoorthy S
    Neuropharmacology; 2017 Feb; 113(Pt A):281-292. PubMed ID: 27743931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Combination of a Dopamine Receptor 2 Agonist and a Kappa Opioid Receptor Antagonist Synergistically Reduces Weight in Diet-Induced Obese Rodents.
    Cicuéndez B; Pérez-García J; Folgueira C
    Nutrients; 2024 Jan; 16(3):. PubMed ID: 38337707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.